A Phase II Trial of Cetuximab (c225) as Therapy for Recurrent Non-Small Cell Lung Cancer in Patients Who Have Received Prior Therapy With Tyrosine Kinase Inhibitor Directed Against the EGFR Pathway.
Phase of Trial: Phase II
Latest Information Update: 05 Sep 2012
At a glance
- Drugs Cetuximab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 25 Sep 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.